Cannatol Rx has been developing ground breaking products with organic ingredients since 2010. Our team consists of doctors, botanists, researchers, compounding pharmacists, and other industry professionals that share the common vision of relieving suffering in those affected with severe disease. 

 

Together we took on the difficult task of developing a product that was formulated with  intensive caregiver feedback on cannabinoid/terpene effective concentrations and ratios. Over several years, our team developed a cannabinoid/terpene intranasal formulation, called CannatolRx Rescue Nasal Spray that has recently been granted a US patent (US10206901B2) entitled, "Method and composition for acute treatment of seizures".  Our patent for an intranasal seizure rescue composition describes  the first cannabinoid-based formulation of its kind in the acute treatment of seizures.   

 

Because it is not yet FDA approved we cannot make claims that it can be taken for rapid cessation of convulsive seizures, but we are gathering pre-clinical data and planning on working with the FDA and the DEA to allow clinical research on our patented formulation. 

 

Although the US patent was recently granted (2019) We have had about 3 years since the initial patent filing to refine the production and there are now hundreds of children with intractable epilepsy or autism that have tried CannatolRx in Colorado alone.  We have several new patents pending surrounding various methods of of pharmacological delivery and formulations of Cannabis sativa L. that we hope to test in multiple clinical studies. 

​

Our production is done in a cGMP facility utilizing cutting edge terpene and cannabinoid extraction methods with the industries’ most advanced equipment.  We adhere to the highest standards of testing and quality control.